International Clinical Neuroscience Journal

Vol. 3 No. 1 (2016)

Effect of Magnetic Tacrine-Loaded Chitosan Nanoparticles on Spatial Learning, Memory, Amyloid Precursor Protein and Seladin-1 Expression in the Hippocampus Of Streptozotocin-Exposed Rats

International Clinical Neuroscience Journal, Vol. 3 No. 1 (2016), 9 July 2016 , Page 25-31
https://doi.org/10.22037/icnj.v3i1.12358

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by memory and cognitive dysfunction due to neuronal cell loss in higher brain centers. Senile plaques containing amyloid β (Aβ) are associated with this disease as well as a reduction in cholinergic neuron numbers. Tacrine is a reversible cholinesterase inhibitor in clinical use to treat moderate forms of AD. Chitosan nanoparticles represent an effective systemic delivery system for drugs. The application of tacrine-loaded chitosan nanoparticles has been shown to selectively increase tacrine concentrations in the brain tissue. In this study, we compared magnetic and non-magnetic tacrine-loaded chitosan nanoparticles for their bioactivity and neuroprotective potency in streptozotocin (stz)-induced neurodegeneration, an accepted animal model for AD. Male rats received a single injection of stz via an implanted cannula into the lateral brain ventricle. Tacrine (tac)-loaded chitosan nanoparticles were delivered into the tail vein. Spatial learning and memory were analyzed using the Morris water maze task. Amyloid precursor protein gene (APP) and seladin-1 gene expression were studied in the hippocampus by real time-PCR. Tac-loaded non-magnetic and tac-loaded magnetic chitosan nanoparticles improved spatial learning and memory after stz treatment with magnetic nanoparticles being most effective. Similarly, tac-loaded chitosan nanoparticles increased seladin-1 and reduced APP gene expression. Again, magnetic nanoparticles were more effective. These data reveal that tac-loaded non magnetic and tac-loaded magnetic chitosan nanoparticles to a higher extent improve brain deficits related to stz application. We conclude that the magnetic target drug delivery system is a promising therapeutic strategy to protect AD-related degenerating in the CNS. 

Keywords:
  • Alzheimer
  • Nanoparticles
  • Tacrine
  • Chitosan
  • Morris Water Maze
  • Seladin-1
  • Amyloid-ß
  • Hippocampus

How to Cite

1.
Hassanzadeh G, Fallahi Z, Khanmohammadi M, Elmizadeh H, Sharifzadeh M, Mahakizadeh S, Zendedel A, Beyer C, Mohseni Kouchesfahani H. Effect of Magnetic Tacrine-Loaded Chitosan Nanoparticles on Spatial Learning, Memory, Amyloid Precursor Protein and Seladin-1 Expression in the Hippocampus Of Streptozotocin-Exposed Rats. Int Clin Neurosci J [Internet]. 2016 Jul. 9 [cited 2025 Mar. 28];3(1):25-31. Available from: https://journals.sbmu.ac.ir/neuroscience/article/view/12358

References

Lim YY, Maruff P, Schindler R, Ott BR, Salloway S, Yoo DC, et al. Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer’s disease. Neurobiology of Aging. 2015.

Ramirez MJ, Lai MK, Tordera RM, Francis PT. Serotonergic therapies for cognitive symptoms in Alzheimer’s disease: rationale and current status. Drugs. 2014;74(7):729-36.

Benhamú B, Martín-Fontecha M, Vázquez-Villa H, Pardo L, López-Rodríguez ML. Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer’s disease. Journal of medicinal chemistry. 2014;57(17):7160-81.

Hassanzadeh G, Hosseini A, Pasbakhsh P, Akbari M, Ghaffarpour M, Takzare N, et al. Trimetazidine Prevents Oxidative Changes Induced in a Rat Model of Sporadic Type of Alzheimer΄ s Disease. Acta Med Iran. 2015;53(1):17-24.

Milovanovic M, Eriksson K, Winblad B, Nilsson S, Lindahl TL, Post C, et al. Alzheimer and platelets: low-density platelet populations reveal increased serotonin content in Alzheimer type dementia. Clinical biochemistry. 2014;47(15):51-3.

Alipour F, Oryan S, Sharifzadeh M, Karimzadeh F, Kafami L, Irannejad H, et al. The Neuroprotective Effect of a Triazine Derivative in an Alzheimer’s Rat Model. Acta Med Iran. 2014;53(1):8-16.

Goure WF, Krafft GA, Jerecic J, Hefti F. Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics. Alzheimers Res Ther. 2014;6(4):42.

Folch J, Junyent F, Verdaguer E, Auladell C, Pizarro JG, Beas-Zarate C, et al. Role of cell cycle re-entry in neurons: a common apoptotic mechanism of neuronal cell death. Neurotoxicity research. 2012;22(3):195-207.

Duan L, Bhattacharyya BJ, Belmadani A, Pan L, Miller RJ, Kessler JA. Stem cell derived basal forebrain cholinergic neurons from Alzheimer’s disease patients are more susceptible to cell death. Mol Neurodegener. 2014;9(3).

Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behavioural brain research. 2011;221(2):555-63.

Costa RO, Ferreiro E, Oliveira CR, Pereira CM. Inhibition of mitochondrial cytochrome c oxidase potentiates Aβ-induced ER stress and cell death in cortical neurons. Molecular and Cellular Neuroscience. 2013;52:1-8.

Antequera D, Bolos M, Spuch C, Pascual C, Ferrer I, Fernandez-Bachiller MI, et al. Effects of a tacrine-8-hydroxyquinoline hybrid (IQM-622) on Aβ accumulation and cell death: involvement in hippocampal neuronal loss in Alzheimer's disease. Neurobiology of disease. 2012;46(3):682-91.

Um H-S, Kang E-B, Koo J-H, Kim H-T, Kim E-J, Yang C-H, et al. Treadmill exercise represses neuronal cell death in an aged transgenic mouse model of Alzheimer's disease. Neuroscience research. 2011;69(2):161-73.

Danysz W, Parsons CG. Alzheimer's disease, β‐amyloid, glutamate, NMDA receptors and memantine–searching for the connections. British journal of pharmacology. 2012;167(2):324-52.

Tsai GE, Falk WE, Gunther J, Coyle JT. Improved cognition in Alzheimer’s disease with short-term D-cycloserine treatment. 2014.

Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430(7000):631-9.

Fernández-Bachiller MaI, Pérez C, González-Munoz GC, Conde S, López MG, Villarroya M, et al. Novel Tacrine− 8-hydroxyquinoline hybrids as multifunctional agents for the treatment of alzheimer’s disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. Journal of medicinal chemistry. 2010;53(13):4927-37.

Birks J. Cholinesterase inhibitors for Alzheimer’s disease (Review). 2012.

Bae KH, Park M, Do MJ, Lee N, Ryu JH, Kim GW, et al. Chitosan oligosaccharide-stabilized ferrimagnetic iron oxide nanocubes for magnetically modulated cancer hyperthermia. ACS nano. 2012;6(6):5266-73.

Häfeli U. Magnetically modulated therapeutic systems. International journal of pharmaceutics. 2004;277(1):19-24.

Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nature protocols. 2006;1(2):848-58.

Schonrock N, Ke YD, Humphreys D, Staufenbiel M, Ittner LM, Preiss T, et al. Neuronal microRNA deregulation in response to Alzheimer’s disease amyloid-beta. PloS one. 2010;5(6):e11070.

Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, et al. Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014:awu064.

Brousseau G, Rourke BP, Burke B. Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: An alternate hypothesis to global cognitive enhancement. Experimental and clinical psychopharmacology. 2007;15(6):546.

Holzgrabe U, Kapková P, Alptüzün V, Scheiber J, Kugelmann E. Targeting acetylcholinesterase to treat neurodegeneration. 2007.

Pepeu G, Giovannini MG. Cholinesterase inhibitors and memory. Chemico-biological interactions. 2010;187(1):403-8.

Suh WH, Suslick KS, Suh Y-H. Therapeutic agents for Alzheimer's disease. Current Medicinal Chemistry-Central Nervous System Agents. 2005;5(4):259-69.

Wilson B, Samanta MK, Santhi K, Kumar KS, Ramasamy M, Suresh B. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine: Nanotechnology, Biology and Medicine. 2010;6(1):144-52.

Yuan X-b, Li H, Yuan Y-b. Preparation of cholesterol-modified chitosan self-aggregated nanoparticles for delivery of drugs to ocular surface. Carbohydrate Polymers. 2006;65(3):337-45.

Wilson B, Samanta MK, Santhi K, Kumar KPS, Ramasamy M, Suresh B. Significant delivery of tacrine into the brain using magnetic chitosan microparticles for treating Alzheimer's disease. Journal of neuroscience methods. 2009;177(2):427-33.

Khan MB, Ahmad M, Ahmad S, Ishrat T, Vaibhav K, Khuwaja G, et al. Bacopa monniera ameliorates cognitive impairment and neurodegeneration induced by intracerebroventricular-streptozotocin in rat: behavioral, biochemical, immunohistochemical and histopathological evidences. Metabolic brain disease. 2015;30(1):115-27.

Roher AE, Esh CL, Kokjohn TA, Castaño EM, Van Vickle GD, Kalback WM, et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimer's & Dementia. 2009;5(1):18-29.

Behl C. Brain aging and late-onset Alzheimer's disease: many open questions. International Psychogeriatrics. 2012;24(S1):S3-S9.

Lien C-F, Molnár Ev, Toman P, Tsibouklis J, Pilkington GJ, Górecki DC, et al. In vitro assessment of alkylglyceryl-functionalized chitosan nanoparticles as permeating vectors for the blood–brain barrier. Biomacromolecules. 2012;13(4):1067-73.

  • Abstract Viewed: 1035 times
  • PDF Downloaded: 389 times

Download Statastics